Large screen approaches to identify novel malaria vaccine candidates

Vaccine

Volumn 33, Issue 52, 2015, Pages 7496-7505

  Davies, D Huw ^a   Duffy, Patrick ^b   Bodmer, Jean Luc ^c   Felgner, Philip L ^a   Doolan, Denise L ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c Cambridge Discovery Park   (United States)

^d QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Antigen discovery; Immunomics; Large scale screen; Protein microarrays; Reverse vaccinology; T cell antigens

Indexed keywords

EPITOPE; MALARIA VACCINE; PARASITE ANTIGEN; PROTEOME; T LYMPHOCYTE ANTIGEN; TRANSCRIPTOME; PROTOZOON ANTIBODY;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; ARTICLE; HUMAN; IMMUNITY; IMMUNIZATION; INDUCED IMMUNITY; MALARIA FALCIPARUM; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PROTEIN MICROARRAY; PROTEOMICS; PROTOZOAL GENETICS; SPOROZOITE; T LYMPHOCYTE; TRANSCRIPTOMICS; VACCINATION; BIOSYNTHESIS; CHEMISTRY; GENETICS; GENOME; GENOMICS; HIGH THROUGHPUT SCREENING; IMMUNOLOGY; INNATE IMMUNITY; MALARIA, FALCIPARUM;

ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; GENOME, PROTOZOAN; GENOMICS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; IMMUNITY, INNATE; MALARIA VACCINES; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; PROTEOME; TRANSCRIPTOME;

EID: 84951905377     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.09.059     Document Type: Article

References (118)

1. Gardner M.J., Hall N., Fung E., White O., Berriman M., et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 2002, 419:498-511.
2. Florens L., Washburn M.P., Raine J.D., Anthony R.M., Grainger M., et al. A proteomic view of the Plasmodium falciparum life cycle. Nature 2002, 419:520-526.
3. Lasonder E., Ishihama Y., Andersen J.S., Vermunt A.M., Pain A., et al. Analysis of the Plasmodium falciparum proteome by high-accuracy mass spectrometry. Nature 2002, 419:537-542.
4. Le Roch K.G., Zhou Y., Blair P.L., Grainger M., Moch J.K., et al. Discovery of gene function by expression profiling of the malaria parasite life cycle. Science 2003, 301:1503-1508.
5. Bozdech Z., Llinas M., Pulliam B.L., Wong E.D., Zhu J., et al. The transcriptome of the intraerythrocytic developmental cycle of Plasmodium falciparum. PLoS Biol 2003, 1:E5.
6. Schwartz L., Brown G.V., Genton B., Moorthy V.S. A review of malaria vaccine clinical projects based on the WHO rainbow table. Malar J 2012, 11:11.
7. Fleischmann R.D., Adams M.D., White O., Clayton R.A., Kirkness E.F., et al. Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science 1995, 269:496-512.
8. Pizza M., Scarlato V., Masignani V., Giuliani M.M., Arico B., et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 2000, 287:1816-1820.
9. Klysik J. Concept of immunomics: a new frontier in the battle for gene function?. Acta Biotheor 2001, 49:191-202.
10. Doolan D.L. Plasmodium immunomics. Int J Parasitol 2011, 41:3-20.
11. malERA Consultative Group on Vaccines A research agenda for malaria eradication: vaccines. PLoS Med 2011, 8:e1000398.
12. Baird J.K. Age-dependent characteristics of protection versus susceptibility to Plasmodium falciparum. Ann Trop Med Parasitol 1998, 92:367-390.
13. Doolan D.L., Dobano C., Baird J.K. Acquired immunity to malaria. Clin Microbiol Rev 2009, 22:13-36. [Table of Contents].
14. Cohen S., Mc G.I., Carrington S. Gamma-globulin and acquired immunity to human malaria. Nature 1961, 192:733-737.
15. Sabchareon A., Burnouf T., Ouattara D., Attanath P., Bouharoun-Tayoun H., et al. Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. Am J Trop Med Hyg 1991, 45:297-308.
16. Nussenzweig R.S., Vanderberg J., Most H., Orton C. Protective immunity produced by the injection of X-irradiated sporozoites of Plasmodium berghei. Nature 1967, 216:160-162.
17. Gwadz R.W., Cochrane A.H., Nussenzweig V., Nussenzweig R.S. Preliminary studies on vaccination of rhesus monkeys with irradiated sporozoites of Plasmodium knowlesi and characterization of surface antigens of these parasites. Bull World Health Organ 1979, 57(Suppl. 1):165-173.
18. Hoffman S.L., Goh L.M., Luke T.C., Schneider I., Le T.P., et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis 2002, 185:1155-1164.
19. Weiss W.R., Jiang C.G. Protective CD8+ T lymphocytes in primates immunized with malaria sporozoites. PLOS ONE 2012, 7:e31247.
20. Schofield L., Villaquiran J., Ferreira A., Schellekens H., Nussenzweig R., et al. Gamma interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites. Nature 1987, 330:664-666.
21. Doolan D.L., Hoffman S.L. The complexity of protective immunity against liver-stage malaria. J Immunol 2000, 165:1453-1462.
22. Tsuji M. A retrospective evaluation of the role of T cells in the development of malaria vaccine. Exp Parasitol 2010, 126:421-425.
23. Beaudoin R.L., Strome C.P.A., Mitchell F., Tubergen T.A. Plasmodium berghei: immunization of mice against the ANKA strain using the unaltered sporozoite as an antigen. Exp Parasitol 1977, 42:1-5.
24. Orjih A.U., Cochrane A.H., Nussenzweig R.S. Comparative studies on the immunogenicity of infective and attenuated sporozoites of Plasmodium berghei. Trans R Soc Trop Med Hyg 1982, 76:57-61.
25. Belnoue E., Costa F.T., Frankenberg T., Vigario A.M., Voza T., et al. Protective T cell immunity against malaria liver stage after vaccination with live sporozoites under chloroquine treatment. J Immunol 2004, 172:2487-2495.
26. Tse S.W., Cockburn I.A., Zhang H., Scott A.L., Zavala F. Unique transcriptional profile of liver-resident memory CD8+ T cells induced by immunization with malaria sporozoites. Genes Immun 2013, 14:302-309.
27. Murphy S.C., Kas A., Stone B.C., Bevan M.J. A T-cell response to a liver-stage Plasmodium antigen is not boosted by repeated sporozoite immunizations. Proc Natl Acad Sci U S A 2013, 110:6055-6060.
28. Aguiar J.C., LaBaer J., Blair P.L., Shamailova V.Y., Koundinya M., et al. High-throughput generation of P. falciparum functional molecules by recombinational cloning. Genome Res 2004, 14:2076-2082.
29. Mehlin C., Boni E., Buckner F.S., Engel L., Feist T., et al. Heterologous expression of proteins from Plasmodium falciparum: results from 1000 genes. Mol Biochem Parasitol 2006, 148:144-160.
30. Vedadi M., Lew J., Artz J., Amani M., Zhao Y., et al. Genome-scale protein expression and structural biology of Plasmodium falciparum and related Apicomplexan organisms. Mol Biochem Parasitol 2007, 151:100-110.
31. Birkholtz L.M., Blatch G., Coetzer T.L., Hoppe H.C., Human E., et al. Heterologous expression of plasmodial proteins for structural studies and functional annotation. Malar J 2008, 7:197.
32. Noe A.R., Espinosa D., Li X., Coelho-Dos-Reis J.G., Funakoshi R., et al. A full-length Plasmodium falciparum recombinant circumsporozoite protein expressed by Pseudomonas fluorescens platform as a malaria vaccine candidate. PLOS ONE 2014, 9:e107764.
33. Doolan D.L., Mu Y., Unal B., Sundaresh S., Hirst S., et al. Profiling humoral immune responses to P. falciparum infection with protein microarrays. Proteomics 2008, 8:4680-4694.
34. Crompton P.D., Kayala M.A., Traore B., Kayentao K., Ongoiba A., et al. A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray. Proc Natl Acad Sci U S A 2010, 107:6958-6963.
35. Trieu A., Kayala M.A., Burk C., Molina D.M., Freilich D.A., et al. Sterile protective immunity to malaria is associated with a panel of novel P. falciparum antigens. Mol Cell Proteomics 2011, 10. 10.1074/mcp. M111.007948.
36. Davies D.H., Liang X., Hernandez J.E., Randall A., Hirst S., et al. Profiling the humoral immune response to infection by using proteome microarrays: high-throughput vaccine and diagnostic antigen discovery. Proc Natl Acad Sci U S A 2005, 102:547-552.
37. Vigil A., Ortega R., Jain A., Nakajima-Sasaki R., Tan X., et al. Identification of the feline humoral immune response to Bartonella henselae infection by protein microarray. PLoS ONE 2010, 5:e11447.
38. Kunnath-Velayudhan S., Salamon H., Wang H.Y., Davidow A.L., Molina D.M., et al. Dynamic antibody responses to the Mycobacterium tuberculosis proteome. Proc Natl Acad Sci U S A 2010, 107:14703-14708.
39. Sundaresh S., Doolan D.L., Hirst S., Mu Y., Unal B., et al. Identification of humoral immune responses in protein microarrays using DNA microarray data analysis techniques. Bioinformatics 2006, 22:1760-1766.
40. Liang L., Leng D., Burk C., Nakajima-Sasaki R., Kayala M.A., et al. Large scale immune profiling of infected humans and goats reveals differential recognition of Brucella melitensis antigens. PLoS Negl Trop Dis 2010, 4:e673.
41. Molina D.M., Pal S., Kayala M.A., Teng A., Kim P.J., et al. Identification of immunodominant antigens of Chlamydia trachomatis using proteome microarrays. Vaccine 2010, 28:3014-3024.
42. Eyles J.E., Unal B., Hartley M.G., Newstead S.L., Flick-Smith H., et al. Immunodominant Francisella tularensis antigens identified using proteome microarray. Proteomics 2007, 7:2172-2183.
43. Sundaresh S., Randall A., Unal B., Petersen J.M., Belisle J.T., et al. From protein microarrays to diagnostic antigen discovery: a study of the pathogen Francisella tularensis. Bioinformatics 2007, 23:i508-i518.
44. Felgner P.L., Kayala M.A., Vigil A., Burk C., Nakajima-Sasaki R., et al. A Burkholderia pseudomallei protein microarray reveals serodiagnostic and cross-reactive antigens. Proc Natl Acad Sci U S A 2009, 106:13499-13504.
45. Tippayawat P., Saenwongsa W., Mahawantung J., Suwannasaen D., Chetchotisakd P., et al. Phenotypic and functional characterization of human memory T cell responses to Burkholderia pseudomallei. PLoS Negl Trop Dis 2009, 3:e407.
46. Beare P.A., Chen C., Bouman T., Pablo J., Unal B., et al. Candidate Q fever serodiagnostic antigens revealed by immunoscreening a Coxiella burnetii protein microarray. Clin Vaccine Immunol 2008.
47. Chen C., Bouman T.J., Beare P.A., Mertens K., Zhang G.Q., et al. A systematic approach to evaluate humoral and cellular immune responses to Coxiella burnetii immunoreactive antigens. Clin Microbiol Infect 2009, 15(Suppl 2):156-157.
48. Vigil A., Ortega R., Nakajima-Sasaki R., Pablo J., Molina D.M., et al. Genome-wide profiling of humoral immune response to Coxiella burnetii infection by protein microarray. Proteomics 2010, 10:2259-2269.
49. Barbour A.G., Jasinskas A., Kayala M.A., Davies D.H., Steere A.C., et al. A genome-wide proteome array reveals a limited set of immunogens in natural infections of humans and white-footed mice with Borrelia burgdorferi. Infect Immun 2008, 76:3374-3389.
50. Doskaya M., Kalantari-Dehaghi M., Walsh C.M., Hiszczynska-Sawicka E., Davies D.H., et al. GRA1 protein vaccine confers better immune response compared to codon-optimized GRA1 DNA vaccine. Vaccine 2007, 25:1824-1837.
51. Mochon A.B., Jin Y., Kayala M.A., Wingard J.R., Clancy C.J., et al. Serological profiling of a Candida albicans protein microarray reveals permanent host-pathogen interplay and stage-specific responses during candidemia. PLoS Pathog 2010, 6:e1000827.
52. Driguez P., Doolan D.L., Loukas A., Felgner P.L., McManus D.P. Schistosomiasis vaccine discovery using immunomics. Parasit Vectors 2010, 3:4.
53. Davies D.H., McCausland M.M., Valdez C., Huynh D., Hernandez J.E., et al. Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice. J Virol 2005, 79:11724-11733.
54. Davies D.H., Molina D.M., Wrammert J., Miller J., Hirst S., et al. Proteome-wide analysis of the serological response to vaccinia and smallpox. Proteomics 2007, 7:1678-1686.
55. Davies D.H., Wyatt L.S., Newman F.K., Earl P.L., Chun S., et al. Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus ankara is comparable to that of Dryvax. J Virol 2008, 82:652-663.
56. Luevano M., Bernard H.U., Barrera-Saldana H.A., Trevino V., Garcia-Carranca A., et al. High-throughput profiling of the humoral immune responses against thirteen human papillomavirus types by proteome microarrays. Virology 2010, 405:31-40.
57. Torres K.J., Castrillon C.E., Moss E.L., Saito M., Tenorio R., et al. Genome-level determination of Plasmodium falciparum blood-stage targets of malarial clinical immunity in the Peruvian Amazon. J Infect Dis 2014.
58. Baum E., Badu K., Molina D.M., Liang X., Felgner P.L., et al. Protein microarray analysis of antibody responses to Plasmodium falciparum in western Kenyan highland sites with differing transmission levels. PLOS ONE 2013, 8:e82246.
59. Nnedu O.N., O'Leary M.P., Mutua D., Mutai B., Kalantari-Dehaghi M., et al. Humoral immune responses to Plasmodium falciparum among HIV-1-infected Kenyan adults. Proteomics Clin Appl 2011, 5:613-623.
60. Barry A.E., Trieu A., Fowkes F.J., Pablo J., Kalantari-Dehaghi M., et al. The stability and complexity of antibody responses to the major surface antigen of Plasmodium falciparum are associated with age in a malaria endemic area. Mol Cell Proteomics 2011, 10. 10.1074/mcp. M111.008326.
61. Travassos M.A., Niangaly A., Bailey J.A., Ouattara A., Coulibaly D., et al. Seroreactivity to Plasmodium falciparum erythrocyte membrane protein 1 intracellular domain in malaria-exposed children and adults. J Infect Dis 2013, 208:1514-1519.
62. Tan X., Traore B., Kayentao K., Ongoiba A., Doumbo S., et al. Hemoglobin S and C heterozygosity enhances neither the magnitude nor breadth of antibody responses to a diverse array of Plasmodium falciparum antigens. J Infect Dis 2011, 204:1750-1761.
63. Hoffman S.L., Billingsley P.F., James E., Richman A., Loyevsky M., et al. Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum Vaccin 2010, 6:97-106.
64. Epstein J.E., Tewari K., Lyke K.E., Sim B.K., Billingsley P.F., et al. Live attenuated malaria vaccine designed to protect through hepatic CD8(+) T cell immunity. Science 2011, 334:475-480.
65. Seder R.A., Chang L.J., Enama M.E., Zephir K.L., Sarwar U.N., et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 2013, 341:1359-1365.
66. Shekalaghe S., Rutaihwa M., Billingsley P.F., Chemba M., Daubenberger C.A., et al. Controlled human malaria infection of Tanzanians by intradermal injection of aseptic, purified, cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg 2014, 91:471-480.
67. Hodgson S.H., Juma E., Salim A., Magiri C., Njenga D., et al. Lessons learnt from the first controlled human malaria infection study conducted in Nairobi, Kenya. Malar J 2015, 14:182.
68. Mordmuller B., Supan C., Sim K.L., Gomez-Perez G.P., Ospina Salazar C.L., et al. Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres. Malar J 2015, 14:117.
69. Felgner P.L., Roestenberg M., Liang L., Hung C., Jain A., et al. Pre-erythrocytic antibody profiles induced by Controlled Human Malaria Infections in healthy volunteers under chloroquine prophylaxis. Sci Rep 2013, 3:3549.
70. Ballou W.R., Cahill C.P. Two decades of commitment to malaria vaccine development: GlaxoSmithKline Biologicals. Am J Trop Med Hyg 2007, 77:289-295.
71. Kester K.E., Cummings J.F., Ofori-Anyinam O., Ockenhouse C.F., Krzych U., et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS, S/AS01B and RTS, S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis 2009, 200:337-346.
72. Efficacy and safety of RTS, S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 2015, RTS, S Clinical Trials Partnership.
73. Campo J.J., Dobano C., Sacarlal J., Guinovart C., Mayor A., et al. Impact of the RTS, S malaria vaccine candidate on naturally acquired antibody responses to multiple asexual blood stage antigens. PLoS ONE 2011, 6:e25779.
74. Campo J.J., Aponte J.J., Skinner J., Nakajima R., Molina D.M., et al. RTS, S vaccination is associated with serologic evidence of decreased exposure to Plasmodium falciparum liver and blood stage parasites. Mol Cell Proteomics 2014.
75. Grubaugh D., Flechtner J.B., Higgins D.E. Proteins as T cell antigens: methods for high-throughput identification. Vaccine 2013, 31:3805-3810.
76. Sette A., Vitiello A., Reherman B., Fowler P., Nayersina R., et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol 1994, 153:5586-5592.
77. Sidney J., Assarsson E., Moore C., Ngo S., Pinilla C., et al. Quantitative peptide binding motifs for 19 human and mouse MHC class I molecules derived using positional scanning combinatorial peptide libraries. Immunome Res 2008, 4:2.
78. Sette A., Sidney J. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics 1999, 50:201-212.
79. Sidney J., del Guercio M-F., Southwood S., Engelhard V.H., Appella E., et al. Several HLA alleles share overlapping peptide specificities. J Immunol 1995, 154:247-259.
80. Southwood S., Sidney J., Kondo A., del Guercio M.F., Appella E., et al. Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol 1998, 160:3363-3373.
81. Doolan D.L., Hoffman S.L., Southwood S., Wentworth P.A., Sidney J., et al. Degenerate cytotoxic T cell epitopes from P. falciparum restricted by multiple HLA-A and HLA-B supertype alleles. Immunity 1997, 7:97-112.
82. Doolan D.L., Southwood S., Chesnut R., Appella E., Gomez E., et al. HLA-DR-promiscuous T cell epitopes from Plasmodium falciparum pre-erythrocytic-stage antigens restricted by multiple HLA class II alleles. J Immunol 2000, 165:1123-1137.
83. Doolan D.L., Southwood S., Freilich D.A., Sidney J., Graber N.L., et al. Identification of Plasmodium falciparum antigens by antigenic analysis of genomic and proteomic data. Proc Natl Acad Sci U S A 2003, 100:9952-9957.
84. Bergmann-Leitner E.S., Mease R.M., De La Vega P., Savranskaya T., Polhemus M., et al. Immunization with pre-erythrocytic antigen CelTOS from Plasmodium falciparum elicits cross-species protection against heterologous challenge with Plasmodium berghei. PLoS ONE 2010, 5:e12294.
85. Doolan D.L., Douradinha B., Roddick J., Robinson L., Taraika J., et al. Immunology, genomics and vaccine development: proteome-wide screening of P. falciparum CD4 and CD8T cell epitopes. 40th Australasian Society of Immunology annual meeting 2010.
86. Picard M.D., Cohane K.P., Gierahn T.M., Higgins D.E., Flechtner J.B. High-throughput proteomic screening identifies Chlamydia trachomatis antigens that are capable of eliciting T cell and antibody responses that provide protection against vaginal challenge. Vaccine 2012, 30:4387-4393.
87. Bouwer H.G., Alberti-Segui C., Montfort M.J., Berkowitz N.D., Higgins D.E. Directed antigen delivery as a vaccine strategy for an intracellular bacterial pathogen. Proc Natl Acad Sci U S A 2006, 103:5102-5107.
88. Hu P.Q., Tuma-Warrino R.J., Bryan M.A., Mitchell K.G., Higgins D.E., et al. Escherichia coli expressing recombinant antigen and listeriolysin O stimulate class I-restricted CD8+ T cells following uptake by human APC. J Immunol 2004, 172:1595-1601.
89. Moffitt K.L., Gierahn T.M., Lu Y.J., Gouveia P., Alderson M., et al. T(H)17-based vaccine design for prevention of Streptococcus pneumoniae colonization. Cell Host Microbe 2011, 9:158-165.
90. Long D., Skoberne M., Gierahn T.M., Larson S., Price J.A., et al. Identification of novel virus-specific antigens by CD4(+) and CD8(+) T cells from asymptomatic HSV-2 seropositive and seronegative donors. Virology 2014, 464-465:296-311.
91. Kaiser K., Matuschewski K., Camargo N., Ross J., Kappe S.H. Differential transcriptome profiling identifies Plasmodium genes encoding pre-erythrocytic stage-specific proteins. Mol Microbiol 2004, 51:1221-1232.
92. Tarun A.S., Peng X., Dumpit R.F., Ogata Y., Silva-Rivera H., et al. A combined transcriptome and proteome survey of malaria parasite liver stages. Proc Natl Acad Sci U S A 2008, 105:305-310.
93. Grifantini R., Bartolini E., Muzzi A., Draghi M., Frigimelica E., et al. Previously unrecognized vaccine candidates against group B meningococcus identified by DNA microarrays. Nat Biotechnol 2002, 20:914-921.
94. Malito E., Biancucci M., Faleri A., Ferlenghi I., Scarselli M., et al. Structure of the meningococcal vaccine antigen NadA and epitope mapping of a bactericidal antibody. Proc Natl Acad Sci U S A 2014, 111:17128-17133.
95. Duffy P.E., Krzych U., Francis S., Fried M. Malaria vaccines: using models of immunity and functional genomics tools to accelerate the development of vaccines against Plasmodium falciparum. Vaccine 2005, 23:2235-2242.
96. Francis S.E., Malkov V.A., Oleinikov A.V., Rossnagle E., Wendler J.P., et al. Six genes are preferentially transcribed by the circulating and sequestered forms of Plasmodium falciparum parasites that infect pregnant women. Infect Immun 2007, 75:4838-4850.
97. Vignali M., Armour C.D., Chen J., Morrison R., Castle J.C., et al. NSR-seq transcriptional profiling enables identification of a gene signature of Plasmodium falciparum parasites infecting children. J Clin Invest 2011, 121:1119-1129.
98. Mok B.W., Ribacke U., Winter G., Yip B.H., Tan C.S., et al. Comparative transcriptomal analysis of isogenic Plasmodium falciparum clones of distinct antigenic and adhesive phenotypes. Mol Biochem Parasitol 2007, 151:184-192.
99. Young J.A., Fivelman Q.L., Blair P.L., de la Vega P., Le Roch K.G., et al. The Plasmodium falciparum sexual development transcriptome: a microarray analysis using ontology-based pattern identification. Mol Biochem Parasitol 2005, 143:67-79.
100. Smith J.D., Gamain B., Baruch D.I., Kyes S. Decoding the language of var genes and Plasmodium falciparum sequestration. Trends Parasitol 2001, 17:538-545.
101. Kraemer S.M., Kyes S.A., Aggarwal G., Springer A.L., Nelson S.O., et al. Patterns of gene recombination shape var gene repertoires in Plasmodium falciparum: comparisons of geographically diverse isolates. BMC Genomics 2007, 8:45.
102. Fried M., Duffy P.E. Adherence of Plasmodium falciparum to chondroitin sulfate A in the human placenta. Science 1996, 272:1502-1504.
103. Fried M., Nosten F., Brockman A., Brabin B.J., Duffy P.E. Maternal antibodies block malaria. Nature 1998, 395:851-852.
104. Salanti A., Staalsoe T., Lavstsen T., Jensen A.T., Sowa M.P., et al. Selective upregulation of a single distinctly structured var gene in chondroitin sulphate A-adhering Plasmodium falciparum involved in pregnancy-associated malaria. Mol Microbiol 2003, 49:179-191.
105. Duffy M.F., Byrne T.J., Elliott S.R., Wilson D.W., Rogerson S.J., et al. Broad analysis reveals a consistent pattern of var gene transcription in Plasmodium falciparum repeatedly selected for a defined adhesion phenotype. Mol Microbiol 2005, 56:774-788.
106. Elliott S.R., Duffy M.F., Byrne T.J., Beeson J.G., Mann E.J., et al. Cross-reactive surface epitopes on chondroitin sulfate A-adherent Plasmodium falciparum-infected erythrocytes are associated with transcription of var2csa. Infect Immun 2005, 73:2848-2856.
107. Hiller N.L., Bhattacharjee S., van Ooij C., Liolios K., Harrison T., et al. A host-targeting signal in virulence proteins reveals a secretome in malarial infection. Science 2004, 306:1934-1937.
108. Marti M., Good R.T., Rug M., Knuepfer E., Cowman A.F. Targeting malaria virulence and remodeling proteins to the host erythrocyte. Science 2004, 306:1930-1933.
109. Sargeant T.J., Marti M., Caler E., Carlton J.M., Simpson K., et al. Lineage-specific expansion of proteins exported to erythrocytes in malaria parasites. Genome Biol 2006, 7:R12.
110. Vincensini L., Richert S., Blisnick T., Van Dorsselaer A., Leize-Wagner E., et al. Proteomic analysis identifies novel proteins of the Maurer's clefts, a secretory compartment delivering Plasmodium falciparum proteins to the surface of its host cell. Mol Cell Proteomics 2005, 4:582-593.
111. Shendure J. The beginning of the end for microarrays?. Nat Methods 2008, 5:585-587.
112. Daily J.P., Scanfeld D., Pochet N., Le Roch K., Plouffe D., et al. Distinct physiological states of Plasmodium falciparum in malaria-infected patients. Nature 2007, 450:1091-1095.
113. Lemieux J.E., Gomez-Escobar N., Feller A., Carret C., Amambua-Ngwa A., et al. Statistical estimation of cell-cycle progression and lineage commitment in Plasmodium falciparum reveals a homogeneous pattern of transcription in ex vivo culture. Proc Natl Acad Sci U S A 2009, 106:7559-7564.
114. Nixon C.P., Friedman J.F., Knopf P.M., Duffy P.E., Kurtis J.D. Protective human immunity as a vaccine discovery tool for falciparum malaria. Transfusion (Paris) 2005, 45:81s-87s.
115. Mutabingwa T.K., Bolla M.C., Li J.L., Domingo G.J., Li X., et al. Maternal malaria and gravidity interact to modify infant susceptibility to malaria. PLoS Med 2005, 2:e407.
116. Raj D.K., Nixon C.P., Nixon C.E., Dvorin J.D., DiPetrillo C.G., et al. Antibodies to PfSEA-1 block parasite egress from RBCs and protect against malaria infection. Science 2014, 344:871-877.
117. Spaccapelo R., Aime E., Caterbi S., Arcidiacono P., Capuccini B., et al. Disruption of plasmepsin-4 and merozoites surface protein-7 genes in Plasmodium berghei induces combined virulence-attenuated phenotype. Sci Rep 2011, 1:39.
118. Roberts L., Enserink M. Malaria. Did they really say.. eradication?. Science 2007, 318:1544-1545.